Shield Therapeutics PLC's (LON:STX) Tim Watts is 'delighted' by successful raise of £25mln through a share placing and subscription at 30p to launch and market its Accrufer iron deficiency treatment in the US.
He also plans to offer an open opportunity to existing shareholders is also being undertaken to raise up to a further £4.2mln to enable the company to finance their own plans for the US marketing of Accrufer since last year.
He says by launching the drug independently, this offers shareholders 'so much more value'.